Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: RainDance Technologies, Expression Analysis; BD; Precision Biomarkers, Affy; and More

NEW YORK (GenomeWeb News) – RainDance Technologies said this week that it had sold its RDT 1000 and sequence enrichment solution to Expression Analysis, a genomic services provider. RainDance said that it was the first sale of its system to a service provider.


Becton Dickinson is investing $200 million in expanding its operations in Mexico, a company official confirmed for GenomeWeb Daily News this week. The firm is expanding a facility in Cuautitlan Izcalli, near Mexico City, and is building a new plant in San Luis Potosi. According to a BD spokesperson, the new facilities make products for the BD Medical segment of the firm.


Precision Biomarkers said that it is the first service provider to offer microRNA profiling using Affymetrix's recently launched GeneChip miRNA Arrays. Precision Biomarkers said that it use the arrays in its biomarker discovery services for pharmaceutical, biotech, and academic customers.


ArrayJet said that it has installed four of its Marathon or Super-Marathon Inkjet Microarrayers during the past 12 months. The firm said that the instruments have been placed at the UHN Microarray Centre in Toronto; USAMRIID in Frederick, Md.; Cornell University in Ithaca, NY; and an undisclosed "large" Bay Area biotech company.


UK charity Breakthrough Breast Cancer announced this week that it has launched "the world's most comprehensive breast cancer database." The Rock database is a free resource that enables researchers to generate detailed computer models and look at complex interactions of all genes and proteins involved in breast cancer.


Mount Desert Island Biological Laboratory in Maine is using Geospiza's genetic analysis software to analyze next-generation sequence data the lab is conducting on sea urchin embryos.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.